Coronavirus Live Updates: September accounted for 41.53 per cent of total COVID-19 cases in India. (File)
India's COVID-19 case count rose to 63,12,585 as 86,821 new coronavirus cases were recorded on Thursday, according to the Health Ministry data. The country now has 9,40,705 active cases, 52.7 lakh recoveries while a total of 98,678 have died due to the disease.
September accounted for 41.53 per cent of the total COVID-19 cases in the country, with 26,21,418 infections of the over 63 lakh cases being reported in the month alone. The past month also saw 33,390 deaths due to the disease, which is around 33.84 per cent of the total 98,678 deaths recorded so far.
According to the Health Ministry data, India's average Covid testing has been increased to conduct more than 15 lakh tests per day, and has exceeded the 140/day/million tests as advised by the World Health Organisation by more than 5 times.Here are the LIVE updates on Coronavirus Pandemic:
Nearly 20,000 employees got COVID-19: Amazon
Amazon said that slightly more than 19,800 of its employees have tested positive for Covid-19 since the start of March.
Data on the e-commerce giant's 1.37 million frontline workers, including those at its Whole Foods Market grocery stores in the United States, showed a lower infection rate than expected, Amazon said.
Amazon has ramped up testing to 50,000 a day across 650 sites, according to the Seattle-based company.
Second Russian Virus Vaccine Passes Early Trials: Report
Early clinical trials of a second Russian coronavirus vaccine have proved successful, its developer said Thursday after Russia boasted of approving the world's first vaccine. Russia's Vektor -- a top-secret state virology research centre in Siberia -- said that early-stage trials were successful for its own experimental vaccine, named EpiVacCorona.
"The first two phases of clinical trials demonstrated the effectiveness and safety of the EpiVacCorona vaccine," Vektor's press department told the Interfax news agency.
Top health body, biopharmaceutical firm develop "Antisera" as potential COVID-19 treatment
The Indian Council of Medical Research (ICMR) in collaboration with a Hyderabad-based biopharmaceutical company has developed "highly purified antisera" prepared by injecting inactivated SARS-CoV2 in horses, which can be a potential treatment for COVID-19.
"The ICMR and Biological E Limited, Hyderabad, have developed highly purified antisera (raised in animals) for prophylaxis and treatment of COVID-19," the top health research body said.
Antisera are blood serum high in antibodies against specific antigens and are injected in humans to help kickstart the immune system to fight specific infections.